Identification of the Targets to Overcome Clinical Problems in Bladder Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 8850
Special Issue Editor
Special Issue Information
Dear Colleagues,
Bladder cancer has been reported to be the 10th most common cancer worldwide, and in 2020, there were more than 573,000 new cases worldwide. In 2022, it is estimated that it will cause 17,100 deaths in the USA. Nevertheless, effective diagnostic and prognostic markers of bladder cancer have yet to be identified.
Recent evidence has suggested that the signaling of steroid hormonal receptors, including the androgen, estrogen and glucocorticoid receptors, was strongly linked with carcinogenesis and progression in bladder cancer. Moreover, the modification of these signaling receptors has the potential to enhance the sensitivity of conventional treatments such as chemotherapy, BCG and radiotherapy.
More recently, it has been shown that there are three molecular subtypes in muscle invasive bladder cancer according to their gene expressions (basal, luminal and p53-like luminal).
Considering clinical challenges such as a lack of effective markers and potent second-line treatments in bladder cancer, a key target in the diagnosis and prognosis of bladder cancer needs to be identified. Therefore, we believe that by exploring potential targets and summarizing and evaluating recent evidence in this Special Issue, we will contribute to prognostic improvement in bladder cancer patients.
Dr. Hiroki Ide
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer
- urothelial carcinoma
- diagnostic marker
- prognostic marker
- chemotherapy
- immunotherapy
- radiotherapy